135040-16-3

Upstream product

• 14035-33-7 1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone 
• 1620-98-0 3,5-di-t-butyl-4-hydroxybenzaldehyde 

Downstream Products

• 721446-17-9 C₃₁H₄₆N₂O₂ 

Relevant academic research and scientific papers

Novel 3,5-diaryl pyrazolines and pyrazole as low-density lipoprotein (LDL) oxidation inhibitor

Compounds 4a-j and 5 were synthesized by cyclocondensation of 3a-j and hydrazine and showed significant LDL-antioxidant activities in the TBARS assay, the lag time of conjugated diene production, the relative electrophoretic mobility (REM) of ox-LDL, the apoB-100 fragmentation, and the macrophage-mediated LDL oxidation. Among compounds 4a-j and 5, 4a was found to be the most active compound as an inhibitor of LDL oxidation and 4a (IC 50=0.1μM) was 6-fold more potent than probucol (IC 50=0.6μM) in the TBARS assay.

Novel 3,5-diaryl pyrazolines as human acyl-CoA:cholesterol acyltransferase inhibitors

A series of pyrazoline derivatives were prepared for evaluating their acyl-CoA:cholesterol acyltransferase activities. 3-(3,5-Di-tert-butyl-4- hydroxyphenyl)-5-(multi-substituted 4-hydroxyphenyl)-2-pyrazolines 4a-i were shown in vitro inhibitory activity on hACAT-1 and -2.